Jubilant DraxImage is dedicated to providing radiopharmaceuticals for the diagnosis and treatment of a variety of diseases. We invite you to learn more about these areas and how our products are used by healthcare professionals to care for their patients.
At Jubilant DraxImage, we are committed to providing healthcare professionals reliable, high-quality macroaggregated albumin (MAA) to enable the accurate diagnosis of patients suspected of having pulmonary embolism. To ensure a quality V/Q scan from start to finish, it’s important to confirm that every unit dose contains at least the recommended 350,000 particle count.
Radiopharmacists and nuclear medicine technologists who prepare unit doses of DRAXIMAGE® MAA should be aware of the suggested number of particles as prescribed in the FDA- and Health Canada-approved package inserts.1 The 350,000 particle count also complies with the Society of Nuclear Medicine and Molecular Imaging and American College of Radiology guidelines.2,3
Our foremost concern is the quality of the V/Q image produced using DRAXIMAGE MAA. Preparing doses with the correct number of particles affects how uniformly particles are distributed across the perfused pulmonary vascular bed and has been shown to yield good to excellent images.4
If you have any questions or would like assistance in ensuring the compliance of your radiopharmacy, contact your Regional Sales Manager or Customer Service at 1-888-633-5343.
This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient. For full Prescribing Information including indications, contraindications, warnings, precautions and adverse events, please see the appropriate product labeling.